Real-world comparison of semaglutide/tirzepatide (GLP‑1/GLP‑1+GIP) vs bariatric surgery. 📉 In a real-world matched study of 14,152 pts: At 2 years: • Surgery: −25.7% total weight loss (TWL) • GLP-1s (semaglutide/tirzepatide): −5.3% TWL (ITT); −7.6% (per-protocol) • HbA1c drop: Surgery −0.5 pts vs GLP-1s −0.2 pts (p<0.001) ⚖️ Conclusion: Surgery delivers greater, sustained weight loss & better glycemic control vs GLP-1s for eligible patients. soard.org/article/S1550-7289…

In the CagriSema trial, patients on sub-maximal doses lost MORE weight than those on the maximum (2.4mg) dose! This demonstrates the need for flexible dosing in the clinic- not all patients need or can tolerate the maximum dose. Insurance companies don't seem to get that... they force patients to increase to the maximum dose. A clever way to get patient to have side effects and discontinue the medication? 🤔 #ADA2025

Summary of REDEFINE 1 and REDEFINE 2 trials with CagriSema, presented this week at #ADA2025 and published in NEJM: REDEFINE 1: • 👥 3,417 participants with obesity or overweight (without diabetes) treated with CagriSema achieved a 22.7% weight loss after 68 weeks, compared to 2.3% with placebo ⚖️ • 🎯 40.4% of participants on CagriSema achieved a weight loss of 25% or more • 📉 The weight loss was slightly below the company's initial expectations of at least 25% REDEFINE 2: • 👥 1,206 participants with obesity or overweight and type 2 diabetes treated with CagriSema achieved a 15.7% weight loss after 68 weeks, best in the category thus far 🥇, compared to 3.1% with placebo ⚖️ • ✅ 89.7% of participants achieved a weight loss of 5% or more • 💉 Mean HbA1c reduction of 2.07% Article links: nejm.org/doi/full/10.1056/NE… nejm.org/doi/full/10.1056/NE…